Adverse outcomes associated with the treatment of Toxoplasma infections

Abstract Adverse outcomes associated with the treatment of Toxoplasma gondii infections in patients with various health backgrounds have not been characterized. The aim of this study was to identify the adverse outcomes and adverse events associated with the current clinical treatments of Toxoplama...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmed M. Shammaa, Thomas G. Powell, Imaan Benmerzouga
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/240f8f79e47c4a98b090dcb198d38659
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:240f8f79e47c4a98b090dcb198d38659
record_format	dspace
spelling	oai:doaj.org-article:240f8f79e47c4a98b090dcb198d386592021-12-02T14:01:21ZAdverse outcomes associated with the treatment of Toxoplasma infections10.1038/s41598-020-80569-72045-2322https://doaj.org/article/240f8f79e47c4a98b090dcb198d386592021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80569-7https://doaj.org/toc/2045-2322Abstract Adverse outcomes associated with the treatment of Toxoplasma gondii infections in patients with various health backgrounds have not been characterized. The aim of this study was to identify the adverse outcomes and adverse events associated with the current clinical treatments of Toxoplama gondii infections using real world data reported to the FDA adverse event reporting system (FAERS). Data submitted to FAERS between 2013 and 2019 was retrieved and analyzed. Reporting odds ratio of death was calculated for the drugs having ≥ 25 reports of adverse outcomes. The adverse event profiles for the same drugs were analyzed and the reporting odds ratio was calculated relative to all other drugs used in the treatment of Toxoplasma infections. There were 503 cases reporting the treatment of Toxoplasma infections in the FAERS database. Death (DE) was the adverse outcome in 102 reports, of which 23 (22.5%) anti-Toxoplasma drugs were listed as the primary suspect drug (PS). Clindamycin (2.04; 1.07–3.90) followed by pyrimethamine (1.53; 0.99–2.36) were the most likely to be associated with death. Adverse events analysis suggest that sulfonamides formulations may have a less favorable safety profile. Our study represents the first real-world analysis of adverse outcomes and events associated with the treatment of Toxoplasma infections. Our findings support the need to better understand the current first-line agents for Toxoplasma infections, in addition to underscoring the need to identify safer regimens.Ahmed M. ShammaaThomas G. PowellImaan BenmerzougaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ahmed M. Shammaa Thomas G. Powell Imaan Benmerzouga Adverse outcomes associated with the treatment of Toxoplasma infections
description	Abstract Adverse outcomes associated with the treatment of Toxoplasma gondii infections in patients with various health backgrounds have not been characterized. The aim of this study was to identify the adverse outcomes and adverse events associated with the current clinical treatments of Toxoplama gondii infections using real world data reported to the FDA adverse event reporting system (FAERS). Data submitted to FAERS between 2013 and 2019 was retrieved and analyzed. Reporting odds ratio of death was calculated for the drugs having ≥ 25 reports of adverse outcomes. The adverse event profiles for the same drugs were analyzed and the reporting odds ratio was calculated relative to all other drugs used in the treatment of Toxoplasma infections. There were 503 cases reporting the treatment of Toxoplasma infections in the FAERS database. Death (DE) was the adverse outcome in 102 reports, of which 23 (22.5%) anti-Toxoplasma drugs were listed as the primary suspect drug (PS). Clindamycin (2.04; 1.07–3.90) followed by pyrimethamine (1.53; 0.99–2.36) were the most likely to be associated with death. Adverse events analysis suggest that sulfonamides formulations may have a less favorable safety profile. Our study represents the first real-world analysis of adverse outcomes and events associated with the treatment of Toxoplasma infections. Our findings support the need to better understand the current first-line agents for Toxoplasma infections, in addition to underscoring the need to identify safer regimens.
format	article
author	Ahmed M. Shammaa Thomas G. Powell Imaan Benmerzouga
author_facet	Ahmed M. Shammaa Thomas G. Powell Imaan Benmerzouga
author_sort	Ahmed M. Shammaa
title	Adverse outcomes associated with the treatment of Toxoplasma infections
title_short	Adverse outcomes associated with the treatment of Toxoplasma infections
title_full	Adverse outcomes associated with the treatment of Toxoplasma infections
title_fullStr	Adverse outcomes associated with the treatment of Toxoplasma infections
title_full_unstemmed	Adverse outcomes associated with the treatment of Toxoplasma infections
title_sort	adverse outcomes associated with the treatment of toxoplasma infections
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/240f8f79e47c4a98b090dcb198d38659
work_keys_str_mv	AT ahmedmshammaa adverseoutcomesassociatedwiththetreatmentoftoxoplasmainfections AT thomasgpowell adverseoutcomesassociatedwiththetreatmentoftoxoplasmainfections AT imaanbenmerzouga adverseoutcomesassociatedwiththetreatmentoftoxoplasmainfections
_version_	1718392187313455104

Adverse outcomes associated with the treatment of Toxoplasma infections

Ejemplares similares